I agree with jasetheace, and as Bluebush also touches on, the device of "D1" being referenced in examination from Rheinmagnet horst Baermann has absolutely no relevance to transdermal technology - The company specializes in fridge magnets among other basic magnet applications.
To be honest I'm quite surprised to see "D1" stuck as the strongest objection over the other 3 citings, and I would certainly expect for one of Europes most respected patent attorneys, the job should not be too difficult from here:
"A skilled person, on reading the disclosure of D1, would not find any teaching or suggestion that the device of D1 could work in this manner, particularly as the active agent may be positioned in such a way that it could not possibly be actively delivered in the same manner."
Couple of points worth highlighting:
1. Gill Jennings & Every LLP "In 2011 the Telegraph UK made a film exploring the reasons for the success of Gill Jennings & Every LLP (GJE), one of the principal European firms specialising exclusively in patents, trade marks, designs and related intellectual property rights.
To fully understand the company, it is important to appreciate the background to its success. Gill Jennings & Every was founded in 1912 by Mr Gill, a patent attorney. It has a long and proud history as one of the foremost patent and trade mark law firms in Europe and will soon celebrate its centenary, sharing the date with the 2012 Olympic Games in London.
Much of GJEs work is in the pharmaceutical and biotechnology industry. It has had strong connections with Cambridge University since the 1980s when the university set up its own Science Park for spin-out businesses. This has since expanded to become known as the Cambridge Cluster. Many new and successful businesses were born, including ARK Therapeutics, which has grown into a multi-million pound business. ARK is also a client of Gill Jennings Every LLP.
Gill Jennings & Every has a great diversity of clients. When it comes to the corporate sector, it works with clients such as BOSE andProcter & Gamble.The nature of this business is different since the work is often more contentious, international and high stake. Some of the most critical and specialist work requires a robust defence of client intellectual property rights in the courts."
2. Inventor(s): EDWARDS JEFFREY; EIJKENBOOM MAUD
Who is Maud Eijkenboom?
Dr Eijkenboom is a product development and commercialisation expert, and was also a former senior R&D scientist at Bayer HealthCare. Her Linkedin profile also states that she is, the inventor on 5 patents"
The 5 Patents
1. CYTOKINE MEDIATING COMPOSITION Pub. No: WO/2007/124540 Inventors: EDWARDS, Jeffrey, D.; EIJKENBOOM, Maud Louisa Johanna Maria; The invention relates to an agent having cytokine mediating activity. In particular the invention relates to a composition comprising a fraction of denatured plasma proteins and at least one metal, metal ion or metal salt thereof, wherein said mixture has cytokine mediating activity. WO/2007/124540 - CYTOKINE MEDIATING COMPOSITION
2. COX-2 INHIBITOR Pub. No: WO/2007/124541 Inventors: EDWARDS, Jeffrey, D.; EIJKENBOOM, Maud Louisa Johanna Maria; The present invention relates to an agent having COX-2 inhibition activity. In particular the present invention relates to a COX-2 inhibitor separated from a mixture of denatured plasma and at least one metal, metal ion or metal salt thereof. (WO/2007/124541 - COX-2 INHIBITOR
3. TISSUE DISRUPTION TREATMENT AND COMPOSITION FOR USE THEREOF Pub. No: WO/2007/025351 Inventors: EDWARDS, Jeffrey, D.; EIJKENBOOM, Maud Louisa Johanna Maria; The present invention relates to an agent having activities in the treatment of a tissue disruption. In particular the invention relates to a composition comprising an effective amount of an active fraction separated from a mixture of plasma and/or serum and at least one metal, metal ion or metal salt thereof, wherein said mixture has been denatured and has an activity selected from one or more of the group consisting of: a) healing tissue disruptions; b) modulating apoptosis; c) modulating the activity of TNF- ; d) modulating the activity of TNF- R; e) modulating the activity of TACE; and f) modulating the activity of a caspase. WO/2007/025351 - TISSUE DISRUPTION TREATMENT AND COMPOSITION FOR USE THEREOF
4. ANALGESIC AND ANTI-INFLAMMATORY COMPOSITION Pub. No: WO/2006/084334 Inventors: EDWARDS, Jeffrey, D.; EIJKENBOOM, Maud Louisa Johanna Maria; PALERMO, John; The present invention relates to an agent having analgesic and anti-inflammatory activity. In particular the present invention relates to a composition comprising an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum and at least one metal, metal ion or metal salt thereof, wherein said mixture has been denatured. WO/2006/084334 - ANALGESIC AND ANTI-INFLAMMATORY COMPOSITION
5. METHOD AND APPARATUS FOR ENHANCED TRANSDERMAL DIFFUSION Pub. No: WO/2009/135246 Inventors: EDWARDS, Jeffrey, D.; EIJKENBOOM, Maud; The present invention relates to a method and apparatus for enhanced transdermal diffusion of substances (such as pharmaceuticals, nutraceuticals, biopharmaceuticals and cosmeceutical) by application of anisotropic magnetic fields having distinctive, complex characteristics WO/2009/135246 - METHOD AND APPARATUS FOR ENHANCED TRANSDERMAL DIFFUSION
In October 2011, Dr Maud Eijkenboom formed a new company under the name of Ingeneus Solutions Pty Ltd, which was formally registered in January 2012:
Dr Maud Eijkenboom Director, R&D and IP Ingeneus Solutions Pty Ltd October 2011 – Present (9 months)
Q: I wonder if Ingeneus Solutions Pty Ltd have anything to do with Melbourne company, Ingeneus Pty Ltd?
I suspect probably not, what's in a name, right? The following news article appears on the Ingeneus Pty Ltd website:
16th December 2011 Ingeneus 'client' V-Patch has featured prominently in the December issue of the Qantas Way in-flight magazine.
Included within the “bright ideas” section of the magazine, V-Patch exemplifies the next generation of wireless ECG telemetry via a non-invasive, wireless vital signs monitoring system. V-Patch’s state-of-the-art technology excels at long and short term monitoring in diverse fields as cardiac diagnosis, clinical drug trials, cardiac rehabilitation, weight management, post operative surveillance, sports medicine and emergency medicine.
The cleverness of the device stems from the “on-board” real-time analysis of each heart beat for abnormal beats. The clinician can select for the identification of 10 specific rhythms, 9 of which account for the majority of transient cardiac events that require treatment. These arrhythmias can be selected individually or collectively, remotely and at any time by the treating physician. When events are detected they are identified, captured and transmitted to the clinician immediately. Ingeneus 'congratulates' V-Patch on its most recent accolade and anticipates future stories of success stemming from the innovative activities of Ingeneus’ medical device technology clients.
So, taken from the article above, "Ingeneus 'client' V-Patch... and Ingeneus 'congratulates' V-Patchon its most recent accolade and anticipates future stories of success stemming from the innovative activities of Ingeneus’'medical device technology clients'... this probably doesn't appear out of the ordinary, with the exception of one small point...
Ingeneus 'is' V-Patch...
Ingeneus Pty Ltd. Axxess Corporate Park Unit 30, 170 Forster Road Mount Waverley VIC Australia 3149 Telephone: +61 3 9558 6334 Fax Number: +61 3 9558 6335 www.ingeneus.com.au
VPMS Asia Pacific Unit 30, 170 Forster Road Mt Waverley Victoria 3150 Tel: +61 3 9558 6334 Fax: +61 3 9558 6335 www.vpatchmedical.com
VPMS Components The V-Patch allows the centralised collection of a range of vital signs from a patient over wireless networks in real time utilising the following components.
The V-Patch is a multi-patented, extended (7 days) but single use biosensor array. It attaches to the skin with sophisticated biodegradable waterproof skin adhesives. The patented donut shaped sensors provide clear and stable ECG signals of diagnostic quality to which the V-Pod is attached.
The V-Pod is a small, non-obtrusive, reusable two-way R-F transceiver that 'snaps' to the V-Patch. On board micro-processor and memory monitors, stores and analyses data collected by the V-Patch and then forwards the information to the matching hand held device (the “V-Cell”).
The V-Cell is a hand held or 'in pocket' device uses a proprietary receiver and cellular phone engine to connect the patient to the internet and from there a variety of IP or MAC addresses including our own V-Central data system.
The V-Central software facilitates the enrolment of physicians and patients into the system. Doctors, after enrolments have an ID and Password set up to access only their patients. Patient data, alarms and alerts are posted to the Doctors own Patient Folio, information and notifications can also be sent to a PDA laptop or other desktop applications. Information can also be sent by fax or SMS text.
OBJ Price at posting:
1.6¢ Sentiment: LT Buy Disclosure: Held
(20min delay)